Is Zepbound (daridorexant) effective for treating sleep apnea?

Zepbound for Sleep Apnea

Critical Clarification: Zepbound vs. Daridorexant

You are asking about the wrong medication—Zepbound (tirzepatide) is a GLP-1 receptor agonist FDA-approved for weight loss and recently approved for obstructive sleep apnea with obesity, NOT daridorexant (Quviviq), which is a sleep medication that does NOT treat sleep apnea. 1, 2

---

Zepbound (Tirzepatide) for Sleep Apnea

Zepbound represents the first FDA-approved pharmacologic agent specifically indicated for moderate to severe obstructive sleep apnea (OSA) in patients with obesity, addressing the primary modifiable risk factor through weight loss. 1

When to Use Zepbound

• Zepbound should be considered as first-line therapy for all overweight and obese patients with OSA, as obesity is the primary modifiable risk factor and weight loss is strongly recommended by the American College of Physicians. 1

• This medication fills a critical gap where previous pharmacologic agents lacked sufficient evidence and were not recommended for OSA treatment. 1, 3

• Weight reduction has historically shown a trend toward improvement in OSA, but has been difficult to achieve and maintain with lifestyle modifications alone—Zepbound provides a pharmacologic solution to this challenge. 1, 3

Treatment Algorithm

For obese patients with moderate to severe OSA:

• Initiate Zepbound alongside CPAP therapy (which remains the gold standard for reducing apnea-hypopnea index, arousal index, and oxygen desaturation). 1, 3

• CPAP demonstrates superior efficacy in improving sleep study measures compared to all other interventions, but Zepbound addresses the underlying pathophysiology through weight loss. 3, 1

• After substantial weight loss (≥10% of body weight), perform a follow-up sleep study to reassess treatment needs, as weight loss may reduce OSA severity and potentially allow for CPAP discontinuation or pressure reduction. 4

Alternative Treatments if CPAP is Refused

• Mandibular advancement devices (MADs) are recommended as first-line alternatives for mild to moderate OSA (AHI <30) in patients who refuse or cannot tolerate CPAP. 3, 4

• Hypoglossal nerve stimulation can be considered for moderate to severe OSA (AHI 15-65) with BMI <32 kg/m² in patients who refuse CPAP. 4

• Maxillomandibular advancement surgery may be considered as salvage therapy for severe OSA after CPAP failure. 4

Critical Pitfalls to Avoid

• Do NOT use daridorexant (Quviviq) to treat sleep apnea—it is an insomnia medication that showed no clinically meaningful effect on apnea-hypopnea index in OSA patients (mean treatment difference of only 0.74 events/hour in mild-moderate OSA and -3.74 events/hour in severe OSA). 2

• Daridorexant's FDA label explicitly warns that clinically meaningful respiratory effects in OSA cannot be excluded, and it should only be used for comorbid insomnia in OSA patients, not as OSA treatment. 2, 5

• Positional therapy is clearly inferior to CPAP and has poor long-term compliance. 3

• Soft palate surgery alone, uvulopalatopharyngoplasty, and other single surgical interventions cannot be recommended as they lack substantial evidence for efficacy. 3, 4

Monitoring and Follow-Up

• Document the patient's understanding of increased cardiovascular complications and mortality risks with untreated OSA. 4

• Reassess OSA severity with polysomnography after achieving ≥10% weight loss on Zepbound to determine if CPAP settings need adjustment or if therapy can be de-escalated. 4

• Monitor for CPAP adherence alongside weight loss efforts, as adherence is critical for effective OSA treatment and cardiovascular risk reduction. 3